Business
Invitation to Presentation of BioInvent's Year-End Report 2025
LUND, SE / ACCESS Newswire / February 26, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2025 on February 26 at 2:00 pm CET. The report will ...
About this update from Bioinvent International Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2025 on February 26 at 2:00 pm CET. The report will be published at 8:00 am CET today.","length":294,"tagName":"p"},{"type":"text","content":"BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.","length":136,"tagName":"p"},{"type":"text","content":"When: Thursday February 26, 2026, at 2:00 pm CET","length":48,"tagName":"p"},{"type":"text","content":"The webcast can be reached at https://bioinvent.events.inderes.com/q4-report-2025.","length":82,"tagName":"p"},{"type":"text","content":"If you wish to ask questions and participate via telephone, please register at the link below. After registration you will be provided with a phone number and a conference ID to access the conference.https://events.inderes.com/bioinvent/q4-report-2025/dial-in.","length":261,"tagName":"p"},{"type":"text","content":"The conference call will be made available on the company website after the call.","length":81,"tagName":"p"},{"type":"text","content":"About BioInventBioInvent International AB (Nasdaq Stockholm:BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.","length":641,"tagName":"p"},{"type":"text","content":"The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.","length":296,"tagName":"p"},{"type":"text","content":"For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +...